AgomAb Therapeutics NV IPO: offering terms from its F-1
AgomAb Therapeutics NV priced its IPO at $16 a share on 6 Feb 2026 and raised $200 million. Its shares trade on Nasdaq as AGMB.
Headlines
- Net loss, 2024
- 46M EUR
- IPO price
- $16
- $200M raised
AgomAb Therapeutics NV IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- AGMB
- IPO price
- $16
- Shares offered
- 12,500,000
- Raised
- $200M
- Registered
- $244M, the amount the filing fee is paid on
- Underwriters
- J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen
- First filed
- 16 Jan 2026
AgomAb Therapeutics NV revenue and profit
In EUR, the currency the company reports in.
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | - | -48M EUR | -46M EUR |
| First nine months of 2025 | - | -43M EUR | -45M EUR |
AgomAb Therapeutics NV share structure and company facts
- Share classes and votes
- Class A: 1 vote
- Employees
- 62
- Headquarters
- Antwerp, Belgium
AgomAb Therapeutics NV shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $16
- Priced 6 Feb 2026
- First close
- $14.65
- -8% on the IPO price
- Latest close
- $8.57
- -46% on the IPO price
AgomAb Therapeutics NV's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from AgomAb Therapeutics NV's newest prospectus (424B4 filed 6 Feb 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.